Circuit Clinical improves clinical trial participation based on the belief that research provides new treatment options in trusted community care settings. We use technology and research expertise to increase patient and physician access while supporting medical advancements.
Circuit Clinical provides specialized expertise to connect underrepresented patients and physicians in the United States to clinical trials through our research services that optimize their experience and reduce the burden of participation for both while meeting regulatory requirements.
This study investigated a novel treatment and appropriate dosing regimen for daily peanut allergen exposure to induce peanut allergen desensitization and increase the amount of tolerated peanut allergen exposure in individuals who are peanut allergic. Circuit partnered with this small biotech to conduct all participant enrollment activities for their study within our Community Research Network, including patient recruitment and facilitating study activities by embedded site research staff.
A phase 2/3, randomized, observer-blind, placebo-controlled study to evaluate the efficacy and safety of an investigational vaccine targeting respiratory syncytial virus (RSV) in adults ≥60 years of age. Circuit Clinical partnered with an industry-leading biotechnology company to enroll patients in their phase 2/3 RSV vaccine study. This study was placed in one of our Community Research Network sites with extensive experience in non-COVID vaccines.
Validation of a saliva-based antibody assay for detection of SARS-CoV-2 involving blood sample and nasopharyngeal swab. Circuit Clinical partnered with a mid-sized biotech company to validate a SARS-CoV-2 assay during the height of the COVID-19 pandemic. This biospecimen collection study targeted enrolling 125 symptomatic individuals between the ages of 18 and 89 who have been tested for SARS-CoV-2.
A Phase 1/2, First-in-Human (FIH), randomized, observer-blind, placebo-controlled, dose-escalation study to assess the safety, reactogenicity, and immunogenicity of a candidate cytomegalovirus (CMV) vaccine comprising recombinant protein and adjuvant when administered in healthy adults. Circuit partnered with a Top 10 pharma company that is a leader in vaccine development to conduct their Phase 1/2 CMV vaccine study in one of our community research sites.
Want to learn more? Reach out to us.